NXTC NextCure, Inc. - Common Stock
$6,92
Preço · Ago 19, 2026
Fundamentais a partir de Ago 6, 2026
Intervalo 52 Semanas
$2–$16
38% of range
Classificação do Analista
BUY
8 analysts
Preço-Alvo
$20
+189% upside
P/E (TTM)
-0.4
ROE
-172.9%
Margem de Lucro Líquido
—
NXTC Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$6.92
Capitalização de Mercado
$25M
P/E (TTM)
-0.4
EPS (TTM)
$-19.65
Receita (TTM)
—
Rendimento div.
—
ROE
-172.9%
Dívida/Capital
—
Intervalo 52 Semanas
$2 – $16
NXTC Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
—
2019-12-31
→
2020-12-31
EPS
$-19.65
2020-12-31
→
2025-12-31
Fluxo de caixa livre
—
2019-12-31
→
2024-12-31
Margens
—
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
NXTC
Mediana de Pares
P/E (TTM)
-0.4
0.8
P/S (TTM)
0.9
6.2
P/B
0.7
3.0
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
NXTC
Mediana de Pares
ROA
-85.2%
-118.6%
ROE
-172.9%
-139.5%
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
NXTC
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
4.1
2.1
Quick Ratio (Índice de Liquidez Seca)
2.5
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
NXTC
Mediana de Pares
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
NXTC
Mediana de Pares
NXTC Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
8 analistas
- Compra forte 2 25,0%
- Compra 5 62,5%
- Manter 1 12,5%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
3 analistas · 2026-08-15
Mediana
$20.00
← Abaixo de todos os alvos
$6.92
Mín
$15.00
Máx
$25.00
Alvo mediano
$20.00
+188,9%
Alvo médio
$20.00
+188,9%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.74%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-2.80 | $-1.97 | -0.83% |
| 31 de Março de 2026 | $-1.87 | $-2.15 | 0.28% |
| 31 de Dezembro de 2025 | $-0.81 | $-2.46 | 1.7% |
| 30 de Setembro de 2025 | $-3.22 | $-4.06 | 0.84% |
| 30 de Junho de 2025 | $-11.29 | $-4.71 | -6.6% |
| 31 de Março de 2025 | $-4.68 | $-4.90 | 0.22% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| NXTC | $50M | -0.7 | — | — | -172.9% | — |
| ESLA | — | -4.5 | — | — | — | — |
| LITS | $16M | -1.0 | 33.8% | — | -81.7% | — |
| GRML | — | — | — | — | -104.9% | — |
| QNCX | $187M | -2.0 | — | — | 700.5% | — |
| LTRN | — | -1.9 | — | — | — | — |
| BYSI | — | — | — | — | 3.1% | — |
| DYAI | — | -4.1 | -11.6% | — | — | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | $22M | $6M | |
| R&D Expense | $45M | $41M | $48M | $54M | $50M | $47M | $34M | |
| SG&A Expense | $13M | $16M | $20M | $22M | $21M | $17M | $10M | |
| Operating Expenses | $58M | $60M | $68M | $76M | $71M | $64M | $44M | |
| Operating Income | $-58M | $-60M | $-68M | $-76M | $-71M | $-41M | $-37M | |
| Interest Expense | · | · | · | · | · | $183.0K | $209.0K | |
| Other Non-op | $2M | $4M | $5M | $1M | $1M | $5M | $4M | |
| Income Tax | $0 | · | · | · | · | · | · | |
| Net Income | $-56M | $-56M | $-63M | $-75M | $-69M | $-37M | $-34M | |
| EPS (Basic) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 | $-1.33 | · | |
| EPS (Diluted) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 | $-1.33 | · | |
| Shares (Basic) | 2,842,448 | 2,330,386 | 27,836,584 | 27,744,209 | 27,615,977 | 27,532,177 | · | |
| Shares (Diluted) | 2,842,448 | 2,330,386 | 27,836,584 | 27,744,209 | 27,615,977 | 27,532,177 | · | |
| EBITDA | $-55M | $-57M | $-64M | $-72M | $-66M | · | $-35M |
Balanço Patrimonial 23
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26M | $28M | $13M | $27M | $12M | $33M | $34M | |
| Prepaid Expense | $2M | $3M | $4M | $4M | $8M | $3M | $4M | |
| Current Assets | $44M | $72M | $113M | $164M | $228M | $288M | $340M | |
| PP&E (Net) | $3M | $5M | $9M | $12M | $14M | $16M | $12M | |
| PP&E (Gross) | $29M | $29M | $29M | $29M | $27M | $24M | $17M | |
| Accum. Depreciation | $25M | $23M | $20M | $17M | $13M | $9M | $5M | |
| Other Non-current Assets | $546.0K | $332.0K | $2M | $3M | $577.0K | $3M | $4M | |
| Total Assets | $50M | $81M | $128M | $184M | $242M | $307M | $356M | |
| Accounts Payable | $2M | $5M | $2M | $4M | $2M | $4M | $2M | |
| Accrued Liabilities | · | · | · | · | $4M | $5M | $5M | |
| Current Liabilities | $11M | $10M | $7M | $9M | $7M | $10M | $15M | |
| Capital Leases | $4M | $5M | $6M | $7M | · | · | · | |
| Other Non-current Liabilities | $526.0K | $661.0K | $785.0K | $899.0K | $2M | · | · | |
| Total Liabilities | $15M | $15M | $14M | $17M | $9M | $13M | $35M | |
| Long-term Debt | · | · | · | $0 | $0 | $4M | $5M | |
| Total Debt | · | · | · | · | · | · | $5M | |
| Common Stock | $4.0K | $2.0K | $28.0K | $28.0K | $28.0K | $28.0K | $27.0K | |
| Paid-in Capital | $471M | $446M | $439M | $431M | $421M | $411M | $403M | |
| Retained Earnings | $-436M | $-380M | $-324M | $-262M | $-187M | $-118M | $-81M | |
| AOCI | $21.0K | $4.0K | $-222.0K | $-1M | $-663.0K | $779.0K | $-38.0K | |
| Stockholders' Equity | $35M | $65M | $114M | $168M | $233M | $294M | $321M | |
| Liabilities + Equity | $50M | $81M | $128M | $184M | $242M | $307M | $356M | |
| Shares Outstanding | 3,505,621 | 2,333,896 | 2,325,259 | 27,774,536 | 27,680,997 | 27,568,802 | 27,499,260 |
Fluxo de Caixa 11
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $3M | $4M | $4M | $4M | $3M | $3M | |
| Stock-based Comp | $3M | $6M | $8M | $10M | $10M | $8M | $2M | |
| Other Non-cash | $1M | $6M | $-2M | $7M | $-2M | · | $-6M | |
| Operating Cash Flow | $-50M | $-41M | $-53M | $-54M | $-57M | $-45M | $-36M | |
| CapEx | · | $474.0K | $820.0K | $2M | $2M | $7M | $3M | |
| Investing Cash Flow | $26M | $55M | $39M | $68M | $37M | $44M | $-304M | |
| Stock Issued | · | $39.0K | $5.0K | · | · | $112.0K | $119.0K | |
| Net Stock Activity | · | $39.0K | · | · | · | · | $119.0K | |
| Financing Cash Flow | $22M | $144.0K | $154.0K | $200.0K | $-3M | $-1M | $243M | |
| Net Change in Cash | $-2M | $15M | $-14M | $14M | $-24M | $-3M | $-97M | |
| Free Cash Flow | · | $-41M | $-54M | $-56M | $-60M | · | $-39M |
Lucratividade 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | -590.5% | |
| Net Margin | · | · | · | · | · | · | -531.5% | |
| EBITDA Margin | · | · | · | · | · | · | -548.0% | |
| ROA | -85.2% | -53.3% | -40.2% | -35.0% | -25.3% | · | -13.4% | |
| ROE | -172.9% | -78.9% | -52.1% | -42.8% | -28.8% | · | -13.7% |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | 7.5 | 16.4 | 18.0 | 34.5 | · | 22.6 | |
| Quick Ratio | 2.5 | 2.9 | 1.9 | 2.9 | 1.9 | · | 2.3 | |
| Debt / Equity | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | -179.3 |
Eficiência 1
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | 0.0 |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $27M | $27M | $27M | $27M | $22M | $6M | |
| Net Income TTM | $-56M | $-56M | $-63M | $-75M | $-69M | $-37M | $-34M | |
| Market Cap | $50M | $259M | $382M | $470M | $1.99B | · | $18.59B | |
| Enterprise Value | · | · | · | · | · | · | $18.56B | |
| P/E | -0.7 | -0.4 | -6.1 | -6.3 | -28.7 | -98.3 | · | |
| P/S | 1.9 | 9.7 | 14.3 | 17.6 | 74.6 | · | 2928.7 | |
| P/B | 1.4 | 4.0 | 3.3 | 2.8 | 8.5 | · | 57.8 | |
| P / Tangible Book | 1.4 | 4.0 | 3.3 | 2.8 | 8.5 | 12.3 | · | |
| P / Cash Flow | -1.0 | -6.4 | -7.2 | -8.7 | -34.8 | · | -521.8 | |
| P / FCF | · | -6.3 | -7.1 | -8.4 | -33.4 | · | -476.7 | |
| EV / EBITDA | · | · | · | · | · | · | -533.6 | |
| EV / FCF | · | · | · | · | · | · | -476.0 | |
| EV / Revenue | · | · | · | · | · | · | 2924.1 | |
| Earnings Yield | -138.5% | -258.1% | -16.4% | -15.9% | -3.5% | -1.0% | · |
Demonstração de Resultados 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $7M | $7M | $7M | $6M | $24M | $8M | $9M | $9M | $12M | $11M | $12M | $11M | $13M | $12M | $13M | $14M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $6M | $5M | $5M | $6M | |
| Operating Expenses | $15M | $10M | $10M | $9M | $27M | $12M | $12M | $12M | $16M | $18M | $16M | $16M | $19M | $17M | $18M | $19M | |
| Operating Income | $-15M | $-10M | $-10M | $-9M | $-27M | $-12M | $-12M | $-12M | $-16M | $-18M | $-16M | $-16M | $-19M | $-17M | $-18M | $-19M | |
| Other Non-op | $202.0K | $309.0K | $321.0K | $321.0K | $484.0K | $646.0K | $852.0K | $955.0K | $1M | $1M | $1M | $1M | $1M | $975.0K | $471.0K | $328.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Net Income | $-15M | $-10M | $-9M | $-9M | $-27M | $-11M | $-12M | $-12M | $-15M | $-17M | $-14M | $-14M | $-18M | $-16M | $-17M | $-19M | |
| EPS (Basic) | $-2.80 | $-1.87 | $-4.75 | $-3.22 | $-11.29 | $-4.70 | $-11.71 | $-4.95 | $-6.61 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.58 | $-0.62 | $-0.68 | |
| EPS (Diluted) | $-2.80 | $-1.87 | $-4.75 | $-3.22 | $-11.29 | $-4.70 | $-11.71 | $-4.95 | $-6.61 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.58 | $-0.62 | $-0.68 | |
| Shares (Basic) | 5,309,724 | 5,239,236 | -30,215,081 | 2,676,116 | 2,374,729 | 2,333,890 | -30,235,036 | 2,331,320 | 2,331,062 | 27,903,040 | -55,606,661 | 27,839,968 | 27,828,741 | 27,774,536 | -55,458,165 | 27,748,844 | |
| Shares (Diluted) | 5,309,724 | 5,239,236 | -30,215,081 | 2,676,116 | 2,374,729 | 2,333,890 | -30,235,036 | 2,331,320 | 2,331,062 | 27,903,040 | -55,606,661 | 27,839,968 | 27,828,741 | 27,774,536 | -55,458,165 | 27,748,844 | |
| EBITDA | $-15M | $-10M | · | $-9M | $-27M | $-12M | · | $-12M | $-16M | $-18M | · | $-16M | $-19M | $-17M | · | $-19M |
Balanço Patrimonial 21
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $15M | $26M | $7M | $5M | $22M | $28M | $28M | $21M | $18M | $13M | $20M | $22M | $30M | $27M | $31M | |
| Prepaid Expense | $2M | $2M | $2M | $4M | $5M | $3M | $3M | $3M | $4M | $7M | $4M | $4M | $5M | $3M | $4M | $6M | |
| Current Assets | $22M | $32M | $44M | $33M | $40M | $59M | $72M | $79M | $90M | $103M | $113M | $123M | $135M | $149M | $164M | $175M | |
| PP&E (Net) | $283.0K | $3M | $3M | $4M | $4M | $5M | $5M | $6M | $7M | $7M | $9M | $10M | $11M | $11M | $12M | $12M | |
| PP&E (Gross) | · | · | $29M | · | · | · | $29M | · | · | · | $29M | · | · | · | $29M | · | |
| Accum. Depreciation | · | · | $25M | · | · | · | $23M | · | · | · | $20M | · | · | · | $17M | · | |
| Other Non-current Assets | $82.0K | $847.0K | $546.0K | $550.0K | $555.0K | $328.0K | $332.0K | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | |
| Total Assets | $23M | $38M | $50M | $40M | $48M | $67M | $81M | $90M | $103M | $115M | $128M | $140M | $153M | $168M | $184M | $190M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $3M | $3M | $5M | $4M | $5M | $4M | $2M | $3M | $3M | $2M | $4M | $2M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Current Liabilities | $6M | $7M | $11M | $11M | $11M | $6M | $10M | $9M | $11M | $10M | $7M | $7M | $8M | $6M | $9M | $6M | |
| Capital Leases | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $7M | · | |
| Other Non-current Liabilities | $455.0K | $491.0K | $526.0K | $561.0K | $596.0K | $629.0K | $661.0K | $693.0K | $725.0K | $755.0K | $785.0K | $815.0K | $843.0K | $872.0K | $899.0K | · | |
| Total Liabilities | $10M | $11M | $15M | $16M | $16M | $11M | $15M | $15M | $17M | $16M | $14M | $13M | $15M | $14M | $17M | $8M | |
| Common Stock | $4.0K | $4.0K | $4.0K | $3.0K | $2.0K | $28.0K | $2.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | |
| Paid-in Capital | $473M | $472M | $471M | $450M | $448M | $447M | $446M | $444M | $442M | $441M | $439M | $437M | $435M | $433M | $431M | $428M | |
| Retained Earnings | $-461M | $-446M | $-436M | $-427M | $-418M | $-391M | $-380M | $-369M | $-357M | $-342M | $-324M | $-310M | $-296M | $-278M | $-262M | $-244M | |
| AOCI | $-3.0K | $-2.0K | $21.0K | $17.0K | $-7.0K | · | $4.0K | $76.0K | $-86.0K | $-182.0K | $-222.0K | $-603.0K | $-925.0K | $-803.0K | $-1M | $-2M | |
| Stockholders' Equity | $12M | $27M | $35M | $24M | $30M | $56M | $65M | $76M | $85M | $99M | $114M | $126M | $138M | $154M | $168M | $182M | |
| Liabilities + Equity | $23M | $38M | $50M | $40M | $48M | $67M | $81M | $90M | $103M | $115M | $128M | $140M | $153M | $168M | $184M | $190M | |
| Shares Outstanding | 4,068,951 | 3,607,555 | 3,505,621 | 2,676,110 | 2,337,516 | 28,006,684 | 2,333,896 | 27,975,840 | 27,975,840 | 27,903,627 | 27,903,027 | 27,839,968 | 27,839,968 | 27,774,536 | 27,774,536 | 27,748,844 |
Fluxo de Caixa 9
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $304.0K | $344.0K | $435.0K | $600.0K | $588.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-10M | $-13M | $-8M | $-6M | $-23M | $-13M | $-7M | $-11M | $-10M | $-13M | $-11M | $-13M | $-15M | $-15M | $-9M | $-15M | |
| CapEx | · | · | · | · | · | · | $-34.0K | $170.0K | $301.0K | $37.0K | $13.0K | $279.0K | $280.0K | $248.0K | $865.0K | $532.0K | |
| Investing Cash Flow | $10M | $1M | $6M | $9M | $4M | $7M | $7M | $18M | $12M | $18M | $4M | $10M | $7M | $18M | $4M | $18M | |
| Stock Issued | $0 | $1M | · | · | · | · | · | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $1M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $22.0K | $1M | $20M | $0 | · | · | $37.0K | $0 | $106.0K | $1.0K | $71.0K | $0 | · | · | $61.0K | $0 | |
| Net Change in Cash | $93.0K | $-11M | $19M | $2M | $-17M | $-6M | $26.0K | $7M | $2M | $5M | $-6M | $-2M | $-8M | $3M | $-4M | $3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-13M | · | · | · | $-15M | · | · |
Lucratividade 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -42.4% | -18.6% | · | -13.3% | -35.7% | -12.0% | · | -10.0% | -12.0% | -12.1% | · | -8.7% | -9.9% | -8.2% | · | -8.5% | |
| ROE | -71.3% | -23.7% | · | -17.4% | -46.6% | -14.2% | · | -11.4% | -13.8% | -13.5% | · | -9.3% | -10.6% | -8.7% | · | -8.8% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 4.6 | · | 3.0 | 3.7 | 10.3 | · | 9.1 | 8.3 | 10.7 | · | 18.7 | 17.3 | 23.8 | · | 29.8 | |
| Quick Ratio | 2.4 | 2.2 | · | 0.7 | 0.5 | 3.8 | · | 3.2 | 1.9 | 1.9 | · | 3.0 | 2.8 | 4.8 | · | 5.3 |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $27M | · | $27M | $27M | $27M | · | $27M | $27M | $27M | · | $27M | $27M | $27M | · | $27M | |
| Net Income TTM | $-60M | $-56M | · | $-58M | $-65M | $-55M | · | $-58M | $-65M | $-65M | · | $-67M | $-71M | $-74M | · | $-75M | |
| Market Cap | $7M | $39M | · | $16M | $13M | $161M | · | $460M | $534M | $747M | · | $431M | $601M | $493M | · | $916M | |
| P/E | -0.1 | -0.5 | · | -0.3 | -0.2 | -0.5 | · | -1.3 | -2.3 | -11.4 | · | -6.4 | -8.5 | -6.7 | · | -12.1 | |
| P/S | 0.2 | 1.4 | · | 0.6 | 0.5 | 6.0 | · | 17.2 | 20.0 | 27.9 | · | 16.1 | 22.5 | 18.5 | · | 34.3 | |
| P/B | 0.5 | 1.4 | · | 0.7 | 0.4 | 2.9 | · | 6.1 | 6.2 | 7.5 | · | 3.4 | 4.3 | 3.2 | · | 5.0 | |
| P / Tangible Book | 0.5 | 1.4 | · | 0.7 | 0.4 | 2.9 | · | 6.1 | 6.2 | 7.5 | · | 3.4 | 4.3 | 3.2 | · | 5.0 | |
| P / Cash Flow | · | -2.9 | · | · | · | -12.4 | · | · | · | -59.2 | · | · | · | -33.4 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -59.1 | · | · | · | -32.8 | · | · | |
| Earnings Yield | -1198.8% | -197.4% | · | -338.7% | -421.0% | -218.1% | · | -77.1% | -43.9% | -8.7% | · | -15.6% | -11.8% | -14.9% | · | -8.2% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Lucro líquido | $-56M | $-56M | $-63M | $-75M | $-69M |
| EPS Diluído | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 4.1 | 7.5 | 16.4 | 18.0 | 34.5 |
| Índice de Liquidez Seca | 2.5 | 2.9 | 1.9 | 2.9 | 1.9 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | — | $-41M | $-54M | $-56M | $-60M |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 31 declarantes · $2.7M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 11 (+4 vs trimestre anterior) | 7 (+3 vs trimestre anterior) | 5 (+2 vs trimestre anterior) | 7 (+3 vs trimestre anterior) | -363K |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| Ikarian Capital, LLC | $461.284 | 288.303 | 17,31% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $443.523 | 277.202 | 16,65% | Ações |
| Sofinnova Investments, Inc. | $356.246 | 222.654 | 13,37% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $273.923 | 171.202 | 10,28% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $250.947 | 156.842 | 9,42% | Ações |
| MILLENNIUM MANAGEMENT LLC | $140.979 | 88.112 | 5,29% | Ações |
| VANGUARD GROUP INC | $136.692 | 9.633 | 5,13% | Ações |
| BOOTHBAY FUND MANAGEMENT, LLC | $135.499 | 84.687 | 5,09% | Ações |
| Squadron Capital Management LLC | $103.142 | 64.464 | 3,87% | Ações |
| Verdad Advisers, LP | $96.722 | 60.451 | 3,63% | Ações |
| Affinity Asset Advisors, LLC | $67.136 | 41.960 | 2,52% | Ações |
| JANE STREET GROUP, LLC | $39.198 | 24.499 | 1,47% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $38.236 | 23.893 | 1,44% | Ações |
| CARDIFF PARK ADVISORS, LLC | $34.933 | 21.833 | 1,31% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $25.814 | 16.134 | 0,97% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $20.000 | 12.500 | 0,75% | Ações |
| DIADEMA PARTNERS LP | $12.387 | 7.742 | 0,46% | Ações |
| Pfizer Inc | $11.533 | 7.001 | 0,43% | Ações |
| BARCLAYS PLC | $9.002 | 5.626 | 0,34% | Ações |
| Persistent Asset Partners Ltd | $3.170 | 1.981 | 0,12% | Ações |
| Tower Research Capital LLC (TRC) | $2.781 | 1.738 | 0,10% | Ações |
| UBS Group AG | $501 | 313 | 0,02% | Ações |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $133 | 83 | 0,00% | Ações |
| BlackRock, Inc. | $117 | 73 | 0,00% | Ações |
| JPMORGAN CHASE & CO | $107 | 61 | 0,00% | Ações |
| MORGAN STANLEY | $106 | 66 | 0,00% | Ações |
| HRT FINANCIAL LP | $58 | 36.450 | 0,00% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $51 | 32 | 0,00% | Ações |
| SBI Securities Co., Ltd. | $32 | 20 | 0,00% | Ações |
| ACADIAN ASSET MANAGEMENT LLC | $30 | 18.982 | 0,00% | Ações |
| Virtu Financial LLC | $18 | 10.991 | 0,00% | Ações |
Executivos da empresa 23 insiders · 11 diretores · 13 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Michael Richman | President & CEO | 30 de Janeiro de 2026 A | — | 0 | 0 | $0 |
| Steven P. Cobourn | Chief Financial Officer | 30 de Janeiro de 2026 A | — | 0 | 0 | $0 |
| Timothy Mayer | Chief Operating Officer | 30 de Janeiro de 2026 A | — | 0 | 0 | $0 |
| Udayan Guha | Chief Medical Officer | 30 de Janeiro de 2026 A | — | 0 | 0 | $0 |
| Kevin G. Shaw | Sr VP, General Counsel | 30 de Janeiro de 2026 A | — | 0 | 0 | $0 |
| Sourav Kundu | Sr VP, Dev. & Mfg. | 30 de Janeiro de 2026 A | — | 0 | 0 | $0 |
| Sol Langermann | Chief Scientific Officer | 31 de Janeiro de 2025 A | — | 0 | 0 | $0 |
| Han Myint | Chief Medical Officer | 29 de Março de 2024 A | — | 0 | 0 | $0 |
| Linda Liu | SVP, Research | 31 de Janeiro de 2022 A | 55.234 | 0 | 0 | $0 |
| Kevin N. Heller | Chief Medical Officer | 14 de Julho de 2020 M | 49.011 | 0 | 0 | $0 |
| James B. Bingham | Chief Development Officer | 28 de Fevereiro de 2020 A | — | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Conselheiro | 18 de Junho de 2026 A | — | 0 | 0 | $0 |
| Ellen Feigal | Conselheiro | 18 de Junho de 2026 A | — | 0 | 0 | $0 |
| John G Houston | Conselheiro | 18 de Junho de 2026 A | — | 0 | 0 | $0 |
| Stephen W Webster | Conselheiro | 18 de Junho de 2026 A | — | 0 | 0 | $0 |
| Elaine V Jones | Conselheiro | 18 de Junho de 2026 A | — | 0 | 0 | $0 |
| KABAKOFF DAVID S | Conselheiro | 18 de Junho de 2026 A | — | 0 | 0 | $0 |
| Garry A Nicholson | Conselheiro | 22 de Junho de 2023 A | — | 0 | 0 | $0 |
| Chau Quang Khuong | Conselheiro | 22 de Junho de 2023 A | 2.711.013 | 0 | 0 | $0 |
| Judith Li | Conselheiro | 11 de Junho de 2020 A | — | 0 | 0 | $0 |
| Stella Xu | Conselheiro | 11 de Junho de 2020 A | 1.103.570 | 0 | 0 | $0 |
| Briggs Morrison | Conselheiro | 11 de Junho de 2020 A | — | 0 | 0 | $0 |
| Timothy M Shannon | Conselheiro | 13 de Junho de 2019 A | 2.254.442 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 3 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Sofinnova Venture Partners IX, L.P. ("SVP IX"), Sofinnova Management IX, L.L.C. ("SM IX"), Dr. James I. Healy ("Healy") | 5 de Março de 2026 | 7,10% | Emenda | Investimento passivo | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC ×3 declarações | 8 de Março de 2024 | — | Declaração inicial | — | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×2 declarações | 22 de Novembro de 2019 | — | Declaração inicial | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 5 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| DCOR · Dimensional ETF Trust | 0,00% | 822 NS | 30 de Abril de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 2.392 NS | 30 de Abril de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 de Julho de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 de Julho de 2026 | Diário |
| IWC · iShares Trust | — | — | 18 de Agosto de 2026 | Diário |